Lacosamidum
 |
Cave: notitiae huius paginae nec praescriptiones nec consilia medica sunt. |
| Cognitores | |
|---|---|
| ChemSpider | 189902 |
| PubChem | 219078 |
| DrugBank | DB06218 |
| Natura chemica | |
| |
| |
| Formula summarum | C 13H 18N 2O 3 |
| Massa molaris | 250.294 g/mol |
| Natura pharmacologica | |
| Codex ATC | N03AX18 (WHO) |
| Semivita biologica | 13 horae |
| Metabolismus | iecore (hepaticus): Demethylatione CYP2C19, CYP2C9, CYP3A4 |
| Excretio | renibus |
| Ad usum therapeuticum | |
| Applicatio | per os, i.v. |
| MedlinePlus | a609028 (Anglice) |
Lacosamidum est medicamentum pharmaceuticum cum virtutibus anticonvulsivis convulsionum partialium apud adultos[1].
Historia[recensere | fontem recensere]
Substantia primum anno 1996 in Houstonia ex N-benzyl-2-acetamidopropionamido derivatum descripta est[2].
Natura lacosamidi[recensere | fontem recensere]
Natura chemica[recensere | fontem recensere]
Nomen IUPAC suum est (2R)-N-benzylo-2-acetamido-3-methoxy-propano-amidum, massa molaris sua 250.294 g/mol. Inest praecursor chemicus benzylamidum C
6H
5CH
2NH
2, quod est benzenum cum NH2. Pariter est derivatum aminoacidorum (—NH—CO—COOH).
Natura pharmacologica[recensere | fontem recensere]
Lacosamidum est medicamentum cum virtutibus anticonvulsivis. Codex ATC est N03AX18 (WHO).
Pharmacodynamica[recensere | fontem recensere]
Lacosamidum canales ionticos natrii tensione reclusos (VGSC) tarde inhibit[3].
Pharmacocinetica[recensere | fontem recensere]
Tempus semivitae biologicum [4] 13 horae sunt. Metabolismus per cytochromatum CYP2C19[5], CYP2C9, CYP3A4 fit. Excretio est per urinas.
Effectus lacosamidi[recensere | fontem recensere]
Effectus adversarii[recensere | fontem recensere]
Lacosamidum enzyma hepatica in sanguinem liberare potest, ut valores sanguinei eorum augeantur.
Usus lacosamidi[recensere | fontem recensere]
Dosis diurna definita (DDD) est 300 mg per die p.o.[6]
Methodus therapeutica[recensere | fontem recensere]
In morbum comitialem tractando dosis initialis sit a 50 mg ad 100 mg die, deinde hebdomade inter 50 et 100 mg die augenti, bis distributum[7], usque a 200 mg ad 400 mg die, commendatur.
Notae[recensere | fontem recensere]
- ↑ Ben-Menachem E., Biton V., Jatuzis D., Abou-Khalil B., Doty P., Rudd G. D. (2007). "Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures". Epilepsia 48 (7): 1308-17
- ↑ Choi D., Stables J. P., Kohn H. (Apr 1996). "Synthesis and anticonvulsant activities of N-Benzyl-2-acetamidopropionamide derivatives". Journal of medicinal chemistry 39 (9): 1907-16
- ↑ Errington A. C., Stöhr T., Heers C., Lees G. (Ian 2008). "The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels". Molecular pharmacology 73 (1): 157-69
- ↑ Goldbook
- ↑ Cawello W., Mueller-Voessing C., Fichtner A. (Mai 2014). "Pharmacokinetics of lacosamide and omeprazole coadministration in healthy volunteers: results from a phase I, randomized, crossover trial". Clinical drug investigation 34 (5): 317-25doi:10.1007/s40261-014-0177-2
- ↑ Systema classificationis Anatomicum Therapeuticum Chemicumque, cap. N03AX cum Pregabalini referentia,
- ↑ Benkert O, Hippius H (2017). Kompendium der Psychiatrischen Pharmakotherapie, Springer (Theodisce)
Nexus externi[recensere | fontem recensere]
- LiverTox de lacosamido (Anglice)
- Lacosamidum et CYP2C19 (Anglice)